Tourmaline Bio (TRML.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow - Longbridge

Quote List Quote List

Event Tracking

Oct28

Tourmaline Bio Inc. Confirms Novartis AG as Beneficial Owner

16:13

Novartis Announces Expiration of Acquisition Offer for Tourmaline Bio

06:32

Sep29

Novartis Initiates Cash Offer to Acquire Tourmaline Bio at $48 Per Share

11:44

Sep9

Multiple Companies Announce Major Mergers and Investments

19:55

Novartis and Tourmaline Bio Merger Termination Fee Terms

10:24

Novartis to Acquire Tourmaline Bio, Inc. for $1.4 Billion to Enhance Cardiovascular Portfolio

05:00

Schedules & Filings

Schedules

Filings

Aug13

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Net Income -23.09 M, EPS -0.8966

May2

Earning Release(EST)

FY2025 Q1 Earning Release (USD) Net Income -22.97 M, EPS -0.894

Mar13

Earning Release(EST)

FY2024 Q4 Earning Release (USD) Net Income -22.24 M, EPS -0.8619

View More

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change

View More